Free Trial

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 5 of 15

→ Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad)
Slide 5
Back to 4
Continue to 6
 
Back to 4
Continue to 6
 

Novartis (NYSE:NVS)

Consensus Rating
Hold
Rating Score
2.0
Ratings Breakdown
0 Buy Ratings, 3 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$115.00 (14.8% Upside)

About Novartis

Novartis logoNovartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/24/2024BMO Capital MarketsBoost Price TargetMarket Perform ➝ Market Perform$114.00 ➝ $116.00
2/23/2024BMO Capital MarketsInitiated CoverageMarket Perform$114.00
1/23/2024Morgan StanleyInitiated CoverageEqual Weight$114.00
12/18/2023HSBCDowngradeBuy ➝ Hold
9/25/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight
7/14/2023HSBCInitiated CoverageBuy
4/26/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy
4/19/2023BTIG ResearchBoost Price Target$75.00 ➝ $85.00
3/27/2023Deutsche Bank AktiengesellschaftUpgradeSell ➝ Hold
1/26/2023CitigroupDowngradeBuy ➝ Neutral
Slide 5
Back to 4
Continue to 6
 

You need to know these two things about AI stocks ASAP… (Ad)

For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.

Go here now for this breaking story.

More From MarketBeat
The Crypto 9-5 Escape Plan
from Crypto 101 Media
7 Stocks That Don’t Need an AI Boost to Move Higher
from MarketBeat
Gold Set to EXPLODE!
from Gold Safe Exchange
7 Best Stocks to Own Right Now
from MarketBeat
He Is Giving Away Bitcoin
from Crypto Swap Profits
7 Stocks Under $20 You Won’t Want to Miss
from MarketBeat